Joe Palca

A vaccine authorized in December for use in India may help solve one of the most vexing problems in global public health: How to supply lower-income countries with a COVID-19 vaccine that is safe, effective and affordable.

The vaccine is called CORBEVAX. It uses old but proven vaccine technology and can be manufactured far more easily than most, if not all, of the COVID-19 vaccines in use today.

Copyright 2022 NPR. To see more, visit https://www.npr.org.

MARY LOUISE KELLY, HOST:

Copyright 2022 NPR. To see more, visit https://www.npr.org.

AUDIE CORNISH, HOST:

Two new studies of a Johnson & Johnson COVID-19 vaccine booster showed promise against the omicron variant at a time when public health officials are urgently recommending booster shots against the fast-spreading variant.

One study was conducted in some 69,000 health care workers in South Africa. Results showed the vaccine reduced hospitalizations by 85% when comparing people who got two doses of the J&J vaccine to people who had a single dose.

The James Webb Space Telescope, on a long and winding journey to its job site a million miles from Earth, has begun the key task of unfurling a giant umbrella-like shield to protect its delicate instruments from the intense radiation of the sun.

Copyright 2022 NPR. To see more, visit https://www.npr.org.

MARY LOUISE KELLY, HOST:

Copyright 2022 NPR. To see more, visit https://www.npr.org.

ELISSA NADWORNY, HOST:

Copyright 2022 NPR. To see more, visit https://www.npr.org.

SCOTT SIMON, HOST:

The most sophisticated space telescope ever built was launched today from the European Space Agency's spaceport in French Guiana.

(SOUNDBITE OF ARCHIVED RECORDING)

UNIDENTIFIED PERSON #1: (Speaking French).

Copyright 2022 NPR. To see more, visit https://www.npr.org.

ARI SHAPIRO, HOST:

Copyright 2022 NPR. To see more, visit https://www.npr.org.

ARI SHAPIRO, HOST:

Copyright 2022 NPR. To see more, visit https://www.npr.org.

MELISSA BLOCK, HOST:

Copyright 2021 NPR. To see more, visit https://www.npr.org.

ARI SHAPIRO, HOST:

Copyright 2021 NPR. To see more, visit https://www.npr.org.

AUDIE CORNISH, HOST:

A Canadian biotech firm is reporting positive results from a large study of its COVID-19 vaccine. What makes it unusual is that the key ingredient of the vaccine is grown in plants.

Medicago has already developed an experimental flu vaccine in Nicotiana benthamian, a plant related to tobacco. When the pandemic struck, the company decided to try to make a COVID-19 vaccine.

Now it appears those efforts have succeeded.

Two new drugs are awaiting authorization from the Food and Drug Administration for treating patients with COVID-19, and both may be effective against the omicron variant.

One is made by Merck, the other by Pfizer.

A new kind of COVID-19 vaccine is about to roll out around the world. Although it won't replace the highly successful vaccines currently available, it could make a difference in the course of the pandemic, especially in lower resourced countries.

Copyright 2021 NPR. To see more, visit https://www.npr.org.

MARY LOUISE KELLY, HOST:

The worrisome omicron variant of the coronavirus has been turning up all over the world. It has not been found in the United States yet. But as the president's chief medical adviser, Anthony Fauci, told NPR today...

Copyright 2022 NPR. To see more, visit https://www.npr.org.

AUDIE CORNISH, HOST:

Pfizer and BioNTech have asked the Food and Drug Administration to authorize their COVID-19 booster shot to all people 18 and older.

The companies say the request is based on results from a study of more than 10,000 volunteers that show vaccine efficacy of 95% or greater for people receiving the booster.

Conventional wisdom says that if you're vaccinated and you get a breakthrough infection with the coronavirus, you can transmit that infection to someone else and make that person sick.

But new evidence suggests that even though that may happen on occasion, breakthrough infections might not represent the threat to others that scientists originally thought.

Copyright 2021 NPR. To see more, visit https://www.npr.org.

AUDIE CORNISH, HOST:

Copyright 2021 NPR. To see more, visit https://www.npr.org.

ARI SHAPIRO, HOST:

Copyright 2021 NPR. To see more, visit https://www.npr.org.

SCOTT SIMON, HOST:

Copyright 2021 NPR. To see more, visit https://www.npr.org.

MARY LOUISE KELLY, HOST:

Pfizer's request to offer a third dose of its COVID-19 vaccine to all Americans 16 or older ran into strong headwinds today.

(SOUNDBITE OF ARCHIVED RECORDING)

Copyright 2021 NPR. To see more, visit https://www.npr.org.

NOEL KING, HOST:

Copyright 2021 NPR. To see more, visit https://www.npr.org.

MARY LOUISE KELLY, HOST:

When Dr. Anthony Fauci spoke recently at a White House briefing about the need for COVID-19 booster shots, buried in his slideshow of charts and data points was a little-noticed scientific paper that offers evidence for a reliable way to predict how much protection a COVID-19 vaccine offers.

The government says people who were vaccinated against COVID-19 eight months ago will need a booster.

That decision is based in part on blood tests that show antibody levels in vaccinated people decline over time.

Some of those tests were done at the University of Texas Medical Branch in Galveston, Texas.

Why there?

With the U.S. in the grips of a frightening surge of coronavirus cases, many parents are understandably eager to know when the COVID-19 vaccine will finally be available for children under 12.

This age group accounts for about 50 million Americans and currently none of them qualify for a shot. But scientists are racing to figure out how one of the COVID-19 vaccines currently available for adults could be given to this age group.

Copyright 2021 NPR. To see more, visit https://www.npr.org.

NOEL KING, HOST:

The Biden administration seems likely to recommend that Americans who got the Moderna or Pfizer COVID vaccines get booster shots after eight months. NPR science correspondent Joe Palca is following this one. Good morning, Joe.

Pages